Clínic Barcelona

Immuneel Therapeutics, Hospital Clínic de Barcelona & IDIBAPS Announce a Strategic collaboration & a License Agreement

Immuneel Therapeutics Private Limited (Immuneel) today announced that it has entered into a multi-asset collaboration and licensing agreement with Hospital Clínic de Barcelona (HCB) and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Under the collaboration which opens up opportunities for co-development of advanced assets to be deployed in Spain and India, Immuneel acquired the exclusive rights to develop and commercialise autologous ARI-0001, a CD19 Chimeric antigen receptor (CAR) T cell therapy, in India.

Related news